Blood Platelet Disorders: Clinical Trials

1,419 trials for Blood Platelet Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

660 completed, 220 unknown, 215 recruiting, 130 terminated. 472 Phase 2, 257 Phase 3, 194 Phase 1, 122 Not applicable, 64 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 2472Completed 204, Unknown 75, Recruiting 67, Terminated 61, Withdrawn 25, Not yet recruiting 22, Active not recruiting 18
Phase 3257Completed 132, Unknown 31, Recruiting 30, Terminated 29, Active not recruiting 17, Withdrawn 10, Not yet recruiting 8
Phase 1194Completed 102, Recruiting 34, Terminated 24, Unknown 11, Active not recruiting 8, Not yet recruiting 7, Withdrawn 7, Enrolling by invitation 1
Not applicable122Completed 53, Recruiting 24, Not yet recruiting 13, Unknown 13, Terminated 9, Withdrawn 7, Active not recruiting 3
Phase 464Completed 26, Unknown 19, Terminated 8, Recruiting 6, Withdrawn 4, Not yet recruiting 1
Early Phase 119Completed 6, Recruiting 4, Not yet recruiting 3, Unknown 3, Withdrawn 2, Terminated 1

Follow Blood Platelet Disorders: new trials by email Literature Review of Blood Platelet Disorders trials Research Report on Blood Platelet Disorders

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy
NM8074 - aHUS - Atypical Hemolytic Uremic Syndrome
Phase 2Not yet recruitingNovelMed Therapeutics122027-11-012026-04-13
A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.
Ianalumab, Eltrombopag - Primary Immune Thrombocytopenia (ITP)
Phase 2Not yet recruitingNovartis Pharmaceuticals362027-02-082026-06-25
Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias
RXIM002 - Immune Thrombocytopenia (ITP)
Phase 1Not yet recruitingRiboX Therapeutics Ltd.272027-02-012026-10-28
Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Phase 2Not yet recruitingJonsson Comprehensive Cancer Center352027-01-302026-11-05
WELL-MPN: A Digital Lifestyle App for Patients With MPNs
WELL-MPN Digital App - Myeloproliferative Neoplasms (MPNs)
Not applicableNot yet recruitingBrigham and Women's Hospital752027-01-012026-09-29
An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1
CAR-T cells targeting CD19 - Pemphigus Vulgaris (PV), ANCA Associated Vasculitis (AAV)
Phase 1 / Phase 2Not yet recruitingUniversity Hospital Tuebingen362027-01-012026-11-12
A Clinical Study Evaluating the Safety and Preliminary Effectiveness of Induced Pluripotent Stem Cell-derived Platelets in Patients With Thrombocytopenia Caused by Allogeneic Hematopoietic Stem Cell Transplantation
iPSC-derived platelets - Thrombocytopenia
Early Phase 1Not yet recruitingRuijin Hospital92026-12-302026-10-29
A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA
Velinotamig specified dose on specified days. - Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
Phase 1 / Phase 2Not yet recruitingCullinan Therapeutics Inc.722026-12-012026-07-31
Sequential Hetrombopag and Recombinant Human Thrombopoietin for Cancer Therapy-Induced Thrombocytopenia
Hetrombopag and recombinant human thrombopoietin, Recombinant Human Thrombopoietin - Thrombocytopenia
Phase 2Not yet recruitingThe First Affiliated Hospital of Zhengzhou University962026-12-012026-11-12
Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia
Zanubrutinib 80mg/d, High dose dexamethasone, Zanubrutinib 160mg/d - Immune Thrombocytopenia
Phase 2Not yet recruitingPeking University People's Hospital902026-12-012026-11-12
Study of LusPACercept in Participants With Myelofibrosis Associated Anemia and Thrombocytopenia
Luspatercept, Pacritinib - Myelofibrosis
Phase 2Not yet recruitingCase Comprehensive Cancer Center502026-12-012026-11-13
Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias
Avatrombopag - Thrombocytopenia
Phase 2Not yet recruitingUniversity of Virginia262026-11-012026-10-26
Efficacy and Safety of Romiplostim N01 for Injection in Promoting Platelet Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation
Romiplostim N01 - Thrombocytopenia, Allogeneic Hematopoietic Stem Cell Transplantation
Phase 2Not yet recruitingThe First Affiliated Hospital of Henan University of Science and Technology872026-11-012026-09-21
A Phase 3 Evaluation of Sutacimig in Glanzmann Thrombasthenia
Sutacimig - Thrombasthenia
Phase 3RecruitingHemab ApS762026-10-272026-11-13
Study of Thyroid Dysfunction in Immune Thrombocytopenic Purpura Patients
Laboratory tests TSH, FT3, FT4 ,anti thyroglobulin antibodies, Anti -TPO antibodies - Thyroid Dysfunction, Immune Thrombocytopenic Purpura
Not yet recruitingSohag University502026-10-252026-10-28
TGD001 Treatment in Thrombotic Microangiopathies
TGD001 - Thrombotic Microangiopathies, ITP Immune-Mediated Thrombocytopenia
Phase 1 / Phase 2RecruitingTargED Biopharmaceuticals B.V.702026-10-252026-11-12
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
Pacritinib, Selinexor - Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Phase 2RecruitingJohn Mascarenhas262026-10-232026-10-27
Neonatal Thrombocytopenia in the NICU
Thrombocytopenia, Neonatal Thrombocytopenia
Not yet recruitingAssiut University1202026-10-202026-10-20
rhTPO for Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Procedures.
rhTPO, Placebo - Thrombocytopenia Associated With Chronic Liver Disease
Phase 3RecruitingMIBIO PTE. LTD.1502026-10-202026-11-06
Hetrombopag for Thrombocytopenia in Patients Scheduled for Elective Hepatic Interventional Diagnostic and Therapeutic Procedures: A Clinical Study
Hetrombopag, Placebo - Thrombocytopenia, Hepatic Interventional Procedure
Phase 3Not yet recruitingZhongda Hospital1082026-10-152026-11-09

Showing 20 of 1419. Sign in to see all of them.

Narrower conditions

Purpura, Thrombocytopenic, Idiopathic (483)  ·  Thrombocytopenia (415)  ·  Thrombocythemia, Essential (229)  ·  Primary Myelofibrosis (193)  ·  Polycythemia Vera (182)  ·  Myeloproliferative Disorders (160)  ·  Myelodysplastic Syndromes (104)  ·  Leukemia, Myeloid, Acute (100)  ·  von Willebrand Diseases (95)  ·  Leukemia, Myelomonocytic, Chronic (91)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (88)  ·  Leukemia (85)  ·  Multiple Myeloma (85)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (84)  ·  Lymphoma, Non-Hodgkin (73)

Broader conditions

Hemic and Lymphatic Diseases (1418)  ·  Hematologic Diseases (1367)  ·  Cytopenia (1010)  ·  Blood Coagulation Disorders (901)  ·  Hemorrhagic Disorders (856)  ·  Pathological Conditions, Signs and Symptoms (807)  ·  Pathologic Processes (794)  ·  Immune System Diseases (648)  ·  Thrombocytopenia (600)  ·  Thrombotic Microangiopathies (590)  ·  Signs and Symptoms (582)  ·  Hemorrhage (560)  ·  Skin Manifestations (550)  ·  Purpura (531)

Interventions

eltrombopag (105)  ·  romiplostim (53)  ·  Dexamethasone (49)  ·  Rituximab (48)  ·  avatrombopag (43)  ·  Cyclophosphamide (32)  ·  fludarabine phosphate (28)  ·  Peripheral Blood Stem Cell Transplantation (27)  ·  Cyclosporine (25)  ·  Blood Specimen Collection (23)  ·  ruxolitinib (23)  ·  Prednisone (22)  ·  Thrombopoietin (22)  ·  Busulfan (21)  ·  Tacrolimus (20)

Sponsors

Peking University People's Hospital (54)  ·  Shandong University (45)  ·  Institute of Hematology & Blood Diseases Hospital, China (41)  ·  GlaxoSmithKline (28)  ·  Novartis Pharmaceuticals (27)  ·  Amgen (26)  ·  Alexion Pharmaceuticals, Inc. (21)  ·  Assistance Publique - Hôpitaux de Paris (21)  ·  Assiut University (21)  ·  National Heart, Lung, and Blood Institute (NHLBI) (20)  ·  Takeda (20)  ·  M.D. Anderson Cancer Center (17)  ·  University Hospital, Bordeaux (17)  ·  National Cancer Institute (NCI) (16)  ·  Fred Hutchinson Cancer Center (14)

Countries

United States (546)  ·  China (285)  ·  France (210)  ·  Italy (175)  ·  United Kingdom (154)  ·  Germany (150)  ·  Spain (120)  ·  Canada (97)  ·  Poland (79)  ·  Australia (76)  ·  Netherlands (73)  ·  Austria (65)  ·  Japan (65)  ·  Belgium (64)  ·  Russia (55)

Top investigators

Lei Zhang, MD (19)  ·  Xiao-Hui Zhang, MD (14)  ·  Xiaohui Zhang, MD (10)  ·  Ming Hou, Dr (6)  ·  John Mascarenhas, MD (5)  ·  Ming Hou (5)  ·  Ming Hou, Dr. (5)

Results publications

PMID 33783815, PMID 19005182, PMID 19846889, PMID 29958797, PMID 40277027, PMID 19671919, PMID 23738544, PMID 24802773, PMID 29419434, PMID 29674506, PMID 34219224, PMID 24254965, PMID 26231455, PMID 26688484, PMID 33995988, PMID 34724566, PMID 12944568, PMID 17077333, PMID 18242413, PMID 20546023, PMID 21533818, PMID 22067384, PMID 22117897, PMID 22409309, PMID 22494019, PMID 23293082, PMID 23470153, PMID 23492914, PMID 24802775, PMID 25566808, PMID 26480931, PMID 27658437, PMID 27734464, PMID 29042367, PMID 29246923, PMID 29445374, PMID 29536526, PMID 29778606, PMID 30369044, PMID 30992268, PMID 32047671, PMID 32499241, PMID 33031789, PMID 33275766, PMID 33632264, PMID 33881463, PMID 34452956, PMID 34794687, PMID 35030255, PMID 38237075

NIH funding

2023 (19), 2018 (10), 2019 (9), 2014 (7), P01CA108671 (7), 2016 (6), P30CA015083 (6), P30CA006973 (5), U01HL072268 (5), 2009 (4), 2017 (4), 2025 (4), P30CA015704 (4), 2004 (3), P01CA015396 (3)